Adams, David S.
Harvard Medical School - David Langenau Lab
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes. Despite improved therapy, relapsing pediatric patients have less than a 30% survival rate. It is therefore important to identify new drug targets for treatment of relapsed T-ALL. In this project,TOX, which is over-expressed in human T-ALL was studied for modulating T-ALL pathogenesis. Through a zebrafish transgenic screen, Tox was shown to act as a collaborating oncogene that increased T-ALL aggression. Data suggest that Tox over-expression results in a HOX11 signature characteristic of rapid cell division, and likely induces molecular pathways in T-ALL pathogenesis unlike T-ALLs expressing only Myc. Uncovering the TOX-regulated molecular pathways may help identify novel drug targets for T-ALL treatment.
Worcester Polytechnic Institute
Major Qualifying Project
All authors have granted to WPI a nonexclusive royalty-free license to distribute copies of the work, subject to other agreements. Copyright is held by the author or authors, with all rights reserved, unless otherwise noted.
Biology and Biotechnology
Chemistry and Biochemistry